Subtype
Malignant Bile Duct Neoplasm
CI-CAN-00003138Explore in graph →
223 active trials3 approved drugs29 evidence items
- NCIt
- C227650
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003138Explore in graph →
Clinical trials
883 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (119)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03781934 | A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations | completed | Phase 1 / Phase 2 | 53 | MedivirINDUSTRY | 4 | Jul 1, 2025 | clinicaltrials |
| NCT07034495 | Laparotomy, Laparoscopy, da Vinci System | completed | — | 486 | National Chung Hsing UniversityOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT05788484 |
| A Study of CDX-585 in Patients With Advanced Malignancies |
| completed |
| Phase 1 |
| 20 |
| Celldex TherapeuticsINDUSTRY |
| 1 |
| Jun 15, 2025 |
| clinicaltrials |
| NCT05253053 | To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 84 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Jun 12, 2025 | clinicaltrials |
| NCT03250273 | A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma | completed | Phase 2 | 44 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT05239169 | Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer | completed | Phase 2 | 40 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT06933576 | Contribution of the EyeMAX™ 11Fr (Micro-Tech) Digital Single-Operator Cholangioscope With a Wide Working Channel(EyeMAX-CREGG) | completed | — | 28 | Clinique Paris-BercyOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT02990481 | A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid Tumors | completed | Phase 1 | 38 | Toray Industries, IncINDUSTRY | 2 | Apr 16, 2025 | clinicaltrials |
| NCT02052778 | A Study of TAS-120 in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 407 | Taiho Oncology, Inc.INDUSTRY | 13 | Mar 27, 2025 | clinicaltrials |
| NCT04137289 | A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer | completed | Phase 1 | 110 | Boehringer IngelheimINDUSTRY | 8 | Mar 25, 2025 | clinicaltrials |
| NCT06888401 | Clinico-demographic Profile of the Patient With Pancreaticobiliary Malignancy Undergoing ERCP in a Tertiary Care Center of Nepal | completed | — | 597 | Kathmandu University School of Medical SciencesOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT04484636 | PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)(PLATON) | completed | N/A | 400 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT03058289 | A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6(IT-01) | completed | Phase 1 / Phase 2 | 111 | Intensity Therapeutics, Inc.INDUSTRY | 2 | Feb 27, 2025 | clinicaltrials |
| NCT05010668 | Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma | completed | Phase 2 | 28 | Fudan UniversityOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT04306367 | Study of Pembrolizumab and Olaparib in Bile Duct Cancer | completed | Phase 2 | 14 | Georgetown UniversityOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT05236699 | A Clinical Study of DEB-TACE Combined With Surufatinib and Camrelizumab in the Treatment of Inoperable or Metastatic ICC(CCGLC-005) | completed | Phase 2 | 23 | Tongji HospitalOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT02349412 | Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers | completed | Phase 3 | 405 | Alliance for Clinical Trials in OncologyOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT04361331 | Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma | completed | Phase 2 | 61 | Shanghai Zhongshan HospitalOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT04028479 | The Registry of Oncology Outcomes Associated With Testing and Treatment(ROOT) | completed | — | 167 | Taproot HealthINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT03999593 | Long-term Morbidity After Surgery for Perihilar Cholangiocarcinoma | completed | — | 60 | University of LiverpoolOTHER | 0 | Dec 17, 2024 | clinicaltrials |
| NCT01640522 | Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms(CaSSY) | completed | N/A | 261 | University of PittsburghOTHER | 1 | Dec 13, 2024 | clinicaltrials |
| NCT06290739 | A Machine-learning Model to Predict Lymph Node Metastasis of Intrahepatic Cholangiocarcinoma | completed | — | 483 | West China HospitalOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT04860154 | Photodynamic Therapy for Cholangiocarcinoma | completed | N/A | 86 | Hepatopancreatobiliary Surgery Institute of Gansu ProvinceOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT04740164 | A Dual Channel Supraglottic Airway Device (LMA Gastro) for Oxygenation in Patients Undergoing ERCP | completed | N/A | 66 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 6, 2024 | clinicaltrials |
| NCT06631352 | Outcomes and Prognostic Factors in Hepatopancreatoduodenectomy(HPD_single) | completed | — | 50 | Seoul National University HospitalOTHER | 0 | Oct 8, 2024 | clinicaltrials |
| NCT06570174 | Oral Protein Supplements for Nutritional and Quality of Life Improvement After Pancreatic Resection in Elderly Patients | completed | N/A | 60 | Yonsei UniversityOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT02989857 | Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)(ClarIDHy) | completed | Phase 3 | 187 | Institut de Recherches Internationales ServierOTHER | 6 | Aug 20, 2024 | clinicaltrials |
| NCT04919642 | Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma | completed | Phase 2 | 55 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05518071 | FLUOPANC-trial - Fluorescence-guided Surgery of Pancreatic and Bileduct Tumors Using cRGD-ZW800-1(FLUOPANC) | completed | Phase 2 | 20 | Leiden University Medical CenterOTHER | 1 | Jun 24, 2024 | clinicaltrials |
| NCT04256980 | Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement | completed | Phase 2 | 34 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | May 30, 2024 | clinicaltrials |
| NCT04742959 | Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 203 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Apr 26, 2024 | clinicaltrials |
| NCT06357117 | Extent of Intrahepatic Infiltration of Perihilar Cholangiocarcinoma | completed | — | 62 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT03201458 | Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer | completed | Phase 2 | 86 | National Cancer Institute (NCI)NIH | 1 | Apr 5, 2024 | clinicaltrials |
| NCT03329950 | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | completed | Phase 1 | 132 | Celldex TherapeuticsINDUSTRY | 1 | Mar 28, 2024 | clinicaltrials |
| NCT04059562 | Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma(TRITICC) | completed | Phase 2 | 28 | Heinrich-Heine University, DuesseldorfOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT03339843 | Multiorgan Metabolic Imaging Response Assessment of Abemaciclib(MiMe-A) | completed | Phase 2 | 85 | Jules Bordet InstituteOTHER | 2 | Mar 15, 2024 | clinicaltrials |
| NCT03665285 | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 109 | NextCure, Inc.INDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT06258824 | MicroRNAs as Bile-based Biomarkers in Pancreaticobiliary Cancers(MIRABILE) | completed | — | 229 | Imperial College LondonOTHER | 1 | Feb 14, 2024 | clinicaltrials |
| NCT00486356 | Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer | completed | Phase 1 | 46 | University of NebraskaOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT01825603 | ADH-1, Gemcitabine Hydrochloride & Cisplatin in Treating Metastatic Pancreatic or Biliary Tract Cancer | completed | Phase 1 | 17 | University of NebraskaOTHER | 1 | Dec 28, 2023 | clinicaltrials |
| NCT03219268 | A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms | completed | Phase 1 | 277 | MacroGenicsINDUSTRY | 8 | Dec 21, 2023 | clinicaltrials |
| NCT03230318 | Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma(FIDES-01) | completed | Phase 2 | 148 | Basilea PharmaceuticaINDUSTRY | 11 | Dec 19, 2023 | clinicaltrials |
| NCT04596865 | Recurrence After Whipple's (RAW) Study | completed | — | 1,484 | University Hospital Plymouth NHS TrustOTHER | 8 | Nov 18, 2023 | clinicaltrials |
| NCT02232633 | A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer | completed | Phase 2 | 45 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 14, 2023 | clinicaltrials |
| NCT03833661 | M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer) | completed | Phase 2 | 159 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 9 | Oct 25, 2023 | clinicaltrials |
| NCT03207347 | A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) | completed | Phase 2 | 37 | University of FloridaOTHER | 1 | Sep 15, 2023 | clinicaltrials |
| NCT05930119 | HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study | completed | Phase 1 | 24 | HutchmedINDUSTRY | 1 | Sep 6, 2023 | clinicaltrials |
| NCT03003065 | Safety and Tumoricidal Effect of Low Dose Foscan PDT in Patients With Inoperable Bile Duct Cancers(PDT) | completed | Phase 2 | 10 | Chinese University of Hong KongOTHER | 1 | Aug 22, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jul 1, 2025source: clinicaltrials